-
1.发明申请Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases 有权抗胆碱能药和白细胞三烯受体拮抗剂的组合用于治疗呼吸系统疾病公开(公告)号：US20060211729A1
公开(公告)日：2006-09-21
申请号：US11376615
申请日：2006-03-16
申请人： Beatrix Fyrnys , Torsten Hoffmann , Mario Weingart , Istvan Szelenyi , Peter Cnota , Ullrich Munzel , Ursula Petzold , Joachim Maus
发明人： Beatrix Fyrnys , Torsten Hoffmann , Mario Weingart , Istvan Szelenyi , Peter Cnota , Ullrich Munzel , Ursula Petzold , Joachim Maus
IPC分类号： A61K31/47 , A61K31/4015
CPC分类号： A61K31/40 , A61K31/4015 , A61K31/47 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.
摘要翻译： 包含抗胆碱能药和至少一种用于治疗呼吸系统疾病的白三烯抑制剂的药物组合物，包括过敏性鼻炎，支气管哮喘，COPD和感冒，以及治疗方法。
-
2.发明申请Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases 审中-公开抗胆碱能药物与4型磷酸二酯酶抑制剂的组合用于治疗呼吸系统疾病公开(公告)号：US20060251589A1
公开(公告)日：2006-11-09
申请号：US11485486
申请日：2006-07-13
申请人： Joachim Maus , Peter Cnota , Istvan Szelenyi , Beatrix Fyrnys
发明人： Joachim Maus , Peter Cnota , Istvan Szelenyi , Beatrix Fyrnys
IPC分类号： A61K31/519 , A61K9/14 , A61K31/401
CPC分类号： A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
摘要： The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
摘要翻译： 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 ，特别是伴有阻塞性或炎症性疾病如慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
3.发明申请Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases 审中-公开抗胆碱能药物与4型磷酸二酯酶抑制剂的组合用于治疗呼吸系统疾病公开(公告)号：US20050175547A1
公开(公告)日：2005-08-11
申请号：US11051463
申请日：2005-02-07
申请人： Joachim Maus , Peter Cnota , Istvan Szelenyi , Beatrix Fyrnys
发明人： Joachim Maus , Peter Cnota , Istvan Szelenyi , Beatrix Fyrnys
IPC分类号： A61K9/00 , A61K31/401 , A61K31/519 , A61K45/06 , A61L9/04 , A61K9/14
CPC分类号： A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
摘要： The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
摘要翻译： 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 特别是那些伴有阻塞性或炎症性慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
4.发明授权Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases 有权抗胆碱能药和白细胞三烯受体拮抗剂的组合用于治疗呼吸系统疾病公开(公告)号：US08268864B2
公开(公告)日：2012-09-18
申请号：US11376615
申请日：2006-03-16
申请人： Beatrix Fyrnys , Torsten Hoffmann , Mario Weingart , Istvan Szelenyi , Peter Jurgen Cnota , Ullrich Munzel , Ursula Petzold , Joachim Maus
发明人： Beatrix Fyrnys , Torsten Hoffmann , Mario Weingart , Istvan Szelenyi , Peter Jurgen Cnota , Ullrich Munzel , Ursula Petzold , Joachim Maus
IPC分类号： A01N43/42 , A01N43/36 , A61K31/47 , A61K31/40 , C07D207/00 , C07D453/04
CPC分类号： A61K31/40 , A61K31/4015 , A61K31/47 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.
摘要翻译： 包含抗胆碱能药和至少一种用于治疗呼吸系统疾病的白三烯抑制剂的药物组合物，包括过敏性鼻炎，支气管哮喘，COPD和感冒，以及治疗方法。
-
5.发明授权Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease 有权抗胆碱能药物与4型磷酸二酯酶抑制剂的组合用于治疗呼吸系统疾病公开(公告)号：US08097605B2
公开(公告)日：2012-01-17
申请号：US12365003
申请日：2009-02-03
CPC分类号： A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
摘要： The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
摘要翻译： 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 ，特别是伴有阻塞性或炎症性疾病如慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括在局部施用（吸入）制剂中和在吸入装置中的应用中呈现这种组合，例如在Novolizer中。
-
6.发明申请Combination of Anticholinergics and Inhibitors of Phosphodiesterase Type 4 For The Treatment of Respiratory Disease 有权抗胆碱能药物与4型磷酸二酯酶抑制剂联合用于治疗呼吸系统疾病公开(公告)号：US20090136429A1
公开(公告)日：2009-05-28
申请号：US12365003
申请日：2009-02-03
IPC分类号： A61K9/12 , A61K31/44 , A61P11/06 , A61K31/4015
CPC分类号： A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
摘要： The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
摘要翻译： 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 ，特别是伴有阻塞性或炎症性疾病如慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.035 秒)
